Moderna Inc and Merck & Co. Inc. reported that their combination therapy reduced the risk of melanoma spreading by 59% after five years. The mid-stage trial enrolled 157 patients and showed a 92.2% overall survival rate for the vaccine-immunotherapy pairing, compared to 71.3% for Keytruda alone. The results confirm earlier findings showing a 49% reduction in the risk of recurrence or death after five years.
Moderna and Merck cancer combo cuts melanoma spread risk
Moderna and Merck's therapy reduced the risk of melanoma spreading by 59% after five years. The combination showed a 92.2% survival rate in the recent mid-stage trial.
Xurve View
Insights:
Xurve View
### Long-Term Survival Gains in Skin Cancer The study tracked patients from 2019 to 2021 to evaluate the experimental vaccine intismeran autogene alongside the immunotherapy Keytruda. The combination group reached a 92.2% survival rate, while the group receiving only Keytruda recorded 71.3%. These results are consistent with three-year follow-up data published in 2023.











